A prespecified interim analysis of the ongoing Phase 3 REGENERATE study has confirmed that obeticholic acid (OCA) is effective in the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Mae Heddlu De Cymru wedi cadarnhau eu bod nhw wedi darganfod corff yn Nash Point ym Mro Morgannwg.
$35 Billion Market! Positive Clinical Trial! Yet Shares Are Down?
Here are four reasons Intercept stock is down despite positive data in the company&apos;s NASH trial.
The New York-based drugmaker announced Tuesday that its medicine Ocaliva is the first to succeed in a final stage trial for nonalcoholic steatohepatitis (NASH), a liver disease that many drugmakers are targeting for potentially lucrative treatments. The drug may be the only available treatment for NASH for more than a year if it wins FDA approval. Intercept’s drug has side effects, and NASH is shaping up to be an especially tricky market.
The competition's heating up over a $35 billion market to treat NASH, a 'silent disease' millions are living with. But some of the early results don't look promising.